Artivion (AORT) investor relations material

Business overview and strategy

• Focuses on aortic valve replacements and devices for aortic dissections and aneurysms, with a core business in allografts, mechanical valves, and surgical sealants.

• Targets double-digit revenue growth and aims to grow EBITDA at twice the revenue growth rate annually.

• Legacy segments grow at low to mid-single digits but are highly profitable and durable, while future growth is driven by high-margin mechanical valves and stent grafts.

• Leverages a global sales force and G&A infrastructure to expand margins and drive EBITDA growth.

• Products are highly differentiated, FDA-approved, and face high barriers to entry, supporting sustainable growth and leverage.

Recent performance and financial outlook

• Achieved 9% revenue growth in the latest quarter, slightly below target but with expectations for improvement.

• Stent grafts and On-X mechanical valves showed strong growth, with On-X achieving high-teens growth rates.

• Full-year guidance was reiterated after a challenging Q1 and a strong Q2, with improved confidence in meeting targets.

• R&D investment is elevated in 2026 due to the Endospan acquisition but expected to normalize to 7%-8% of sales in 2027.

• Free cash flow was neutral in 2025 due to one-time investments, but future years are expected to see significant positive cash flow.

Product pipeline and innovation

• Pipeline includes high-growth, high-margin products such as AMDS and NEXUS, both recently receiving PMA approval.

• NEXUS is a platform with future derivatives targeting adjacent aortic arch segments, with a full U.S. launch planned for January next year.

• The Endospan acquisition solidifies the product pipeline for over five years, with ongoing trials for next-generation products like Arcevo.

• R&D is concentrated on one segment, enabling a new PMA every two years and maximizing innovation efficiency.

• Manufacturing scale-up for NEXUS is underway to ensure sufficient inventory for the U.S. launch.